Biocon is currently trading at Rs 334.45, up by 0.50 points or 0.15% from its previous closing of Rs 333.95 on the BSE.
The scrip opened at Rs 335.75 and has touched a high and low of Rs 339.45 and Rs 333.30 respectively. So far 38090 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52-week high of Rs 404.60 on 21-Jan-2025 and a 52-week low of Rs 270.00 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs 339.45 and Rs 327.95 respectively. The current market cap of the company is Rs 40676.33 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.38% and 17.97% respectively.
Biocon has raised Rs 600 crore through Commercial Papers (CPs) on private placement basis. Maturity of the said Commercial Papers will be on September 30, 2025.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: